PHIOW - Phio Pharmaceuticals Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.0900
0.0000 (0.00%)
At close: 9:30AM EST
Stock chart is not supported by your current browser
Previous Close0.0900
Open0.0900
Bid0.0270 x N/A
Ask0.0900 x 1200
Day's Range0.0900 - 0.0900
52 Week Range0.0900 - 0.0900
Volume0
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PHIO: Third Quarter 2019 Financial & Operational Update
    Zacks Small Cap Research

    PHIO: Third Quarter 2019 Financial & Operational Update

    By John Vandermosten, CFA NASDAQ:PHIO Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported third quarter 2019 results and filed its Form 10-Q on November 12, 2019. Since the beginning of the year, the company has announced a several new collaborations with partners including Glycostem Therapeutics, Helmholtz Zentrum Munchen and Carisma Therapeutics. Research and development efforts have put the

  • Zacks Small Cap Research

    PHIO: Overcoming Immune Checkpoints

    By John Vandermosten, CFA NASDAQ:PHIO READ THE FULL PHIO RESEARCH REPORT Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported second quarter 2019 results and filed its Form 10-Q on August 12, 2019. Since ...

  • Zacks Small Cap Research

    PHIO: Two Compounds Entering Clinic in 2020

    Since the beginning of the year, the company has announced a new collaborations with Glycostem Therapeutics, the promotion of Dr. Gerrit Dispersyn to CEO and the appointment of Dr. John Barrett as CDO. Phio’s lead candidate, RXI-762, is pursuing immuno-oncology indications in collaboration with Center for Cancer Immune Therapy (CCIT) and Iovance Biotherapeutics. Development efforts are centered on reducing the immune checkpoints that appear on the surface of tumor infiltrating lymphocytes (TILs) in an approach that can be layered on to current manufacturing processes.

  • Zacks Small Cap Research

    PHIO: Activation in the Tumor Microenvironment

    Phio Pharmaceuticals Corp. (PHIO) reported fourth quarter and full year results and filed its Form 10-K on March 27, 2018. Key operational events in 2018 include data presentations on NK cells, collaborations with Karolinska Institutet and Iovance Biotherapeutics and positive results from the Phase II assets. Other accomplishments include a change in the corporate name to Phio Pharmaceuticals, publication of sd-rxRNA immuno-oncology successes in Molecular Therapy and the elevation of Dr. Gerrit Dispersyn to Chief Executive Officer.